Media Firms Will Provide a Market Name
Yes, after FDA approval, Anavex will most likely engage a professional media firm to work out a new market name of their being-sold drugs.
"Anavex 2-73 Plus" not likely to be the name.
The firm will pull in target populations (older people) and form focus groups. Names will be tossed around in the room. Cameras will record how these potential, future patients respond to how the names sound, how they are pronounced, along with reactions to held up images of proposed colorful graphics for each drug.
Commercial drugs have two names. A trade name, and an assigned generic name. The generic name is long, with lots syllables, seldom used, something like dorglecontramub.
The trade name starts with a capital letter, say, "Alzgone."
There are FDA rules that affect this (of which I don't know the details). As I recall, the assigned trade name cannot be overly specific in desired outcomes. "Alzgone" is probably prohibited.
"Euneurogen" might be acceptable. "Eu-" means good or proper, "neuro" means nerve or brain, "-gen" means maker or origin.
Will be fun to watch.
News 
Market Data 
Discover 
AI
